Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine
Caso Clínico 17 | Médicamente, la web de Novartis para Profesionales Sanitarios
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study - ScienceDirect
May 30 - June 3, 2014 Chicago, Illinois - ppt download
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3 ...
Hematología y Oncología: ASCO 2015 - COMBI-d: Improved OS with Dabrafenib + Trametinib vs Dabrafenib + Placebo in mutated BRAF in Metastatic Melanoma (in 3 slides)
Comparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings
View of Cutaneous Melanoma – A Review of Systemic Therapies | Acta Dermato-Venereologica
Confirmed survival benefit of combined BRAF and MEK inhibition in advanced BRAFV600 mutant melanoma
Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
Combined BRAF and MEK Inhibition for Patients with Advanced Melanoma
Congreso Americano_Highlights junio 2021 - Resumen nº6
Un anno di targeted therapy nel melanoma - OncoInfo
Frontiers | Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Female patients with melanoma have an improved response to BRAF/MEK... | Download Scientific Diagram
MELANOMA: tratamiento de primera línea
Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials -
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - The Lancet Oncology
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
Study designs for (a) part 1 and (b) part 2 of COMBI-i ALT, alanine... | Download Scientific Diagram
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review | JACC: CardioOncology
